3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
19
Leukemia
16
Myelodysplastic Syndromes
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neuroblastoma
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Monocytic, Acute
3
Leukemia, Megakaryoblastic, Acute
3
Leukemia, Erythroblastic, Acute
3
Congenital Abnormalities
3
Sarcoma, Ewing
2
Neoplasms, Plasma Cell
2
Myeloproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Graft vs Host Disease
2
Burkitt Lymphoma
2
Anemia, Refractory, with Excess of Blasts
2
Sarcoma
1
Recurrence
1
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Busulfan
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled